Director Machine Learning, Drug Discovery Analytics Revolution MedicinesDirector Machine Learning, Drug Discovery AnalyticsRedwood City, California$273,000–$321,000 / yearThe successful candidate will play a key role in advancing a data-driven discovery strategy by designing predictive models, deploying innovative algorithms, and translating insights into actionable decisions that improve the speed and success of the discovery of medicines for patients with RAS-driven cancers. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director / Vice President, Biology & Translational Pharmacology ProfluentExecutive Director / Vice President, Biology & Translational PharmacologyEmeryville, CAProvide accountable leadership for cross-functional therapeutic program teams, integrating translational biology, genome editing, protein engineering, delivery, pharmacology, bioanalytics, CMC, regulatory, and preclinical development expertise. Outstanding written and verbal communication skills, with the ability to tailor scientific and strategic messages for audiences ranging from technical project teams to senior executives, board members, external advisors, partners, and generalist investors.
Associate Creative Director, Copy EvokeAssociate Creative Director, CopySan Francisco, CARemoteWe consider compensation more than just a base salary - that's why we also offer an exceptional range of flexible benefits, personal support and tailored learning and development opportunities all designed to help you realize your full potential both in life and at work. Mentor a team of Copywriters and Senior Copywriters, developing their writing skills and strategic thinking.
Associate Director, Regulatory CMC VaxcyteAssociate Director, Regulatory CMCSan Carlos, California$180,000–$210,500 / yearVaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, which have serious and costly health consequences when left unchecked. Our work together is guided by four enduring core values: *RETHINK CONVENTION: We bring creative and intellectual diversity to every facet of the work we do in order to innovate and re-innovate the way vaccines are delivered.
Associate Director, Clinical Data Management Revolution MedicinesAssociate Director, Clinical Data ManagementRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Senior Director, Talent Acquisition & HRBP Maze TherapeuticsSenior Director, Talent Acquisition & HRBPSouth San Francisco, CA$270,000–$330,000 / yearThe company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution MedicinesExecutive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, California$265,000–$331,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Regional Insights and Engagement Director, Lung, Central Rockies Revolution MedicinesRegional Insights and Engagement Director, Lung, Central RockiesRedwood City, CaliforniaRemote$231,000–$254,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of RevMed’s US commercialization strategy; Uncovers, prioritizes, and communicates market insights, challenges/barriers, and solutions to the organization.
Associate Director, Clinical Quality Assurance Revolution MedicinesAssociate Director, Clinical Quality AssuranceRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Senior Director, Head of Transactions & Partnering Revolution MedicinesSenior Director, Head of Transactions & PartneringRedwood City, CaliforniaRemote$244,000–$305,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role partners closely with Business Development leadership and cross-functional stakeholders across Research, Development, Commercial, Finance, Legal, Intellectual Property, and Executive Management to advance high-priority opportunities from initial assessment through successful execution.
Senior Director, Molecule Global Regulatory Lead Revolution MedicinesSenior Director, Molecule Global Regulatory LeadRedwood City, California$244,000–$305,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provide strategic oversight for the planning and execution of major regulatory submissions, including INDs, CTAs, amendments, expedited designation requests, marketing applications, and lifecycle submissions.
Senior Director, Compliance Revolution MedicinesSenior Director, ComplianceRedwood City, California$244,000–$305,000 / yearThe Senior Director, Compliance will support the Vice President, Compliance to implement and continuously enhance a comprehensive compliance program that spans healthcare, research, manufacturing, export controls, economic sanctions, trade and tariff-related compliance, general corporate compliance and other global business conduct requirements applicable to a growing multinational organization. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Compliance & Training Revolution MedicinesAssociate Director, Clinical Operations Compliance & TrainingRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Executive Director, Clinical Development Revolution MedicinesExecutive Director, Clinical DevelopmentRedwood City, California$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. In this critical role, you will be responsible for developing the strategic plans and ensuring efficient operational execution of the molecule(s)’ clinical development program in one or more disease indications, from early-stage studies to regulatory submissions and potential commercialization.
Associate Director, Precision Medicine & Companion Diagnostics Revolution MedicinesAssociate Director, Precision Medicine & Companion DiagnosticsRedwood City, California$186,000–$233,000 / yearRevolution Medicines is offering a highly visible opportunity for talented and motivated individual to join our Precision Medicine Companion Diagnostics team as an Associate Director, Companion Diagnostics within the Translational Medicine function, which supports CDx development across RevMed portfolio. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Portfolio Omnichannel (Lung HCP) Revolution MedicinesDirector, Portfolio Omnichannel (Lung HCP)Redwood City, California$211,000–$264,000 / yearThe Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Early Clinical Development Revolution MedicinesExecutive Director, Early Clinical DevelopmentRedwood City, California$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Revolution MedicinesAssociate Director, Clinical OperationsRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Proven experience working with investigators, external experts and regulatory agencies and oversight of Contract Research Organizations and third-party vendors including realigning with CRO partners when deliverables are at risk, negotiating solutions and leading After Action Reviews to share lessons learned.
Senior Director, Global Patient Safety Operations Revolution MedicinesSenior Director, Global Patient Safety OperationsRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director will provide broad oversight across case processing, vendor governance, safety systems and processes, aggregate reporting operations, partner interfaces, and operational readiness while developing leaders and serving as a key advisor to cross-functional stakeholders.
Senior Director, Global Patient Safety Quality and Compliance Revolution Medicines IncSenior Director, Global Patient Safety Quality and ComplianceRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director will provide broad oversight across case processing, vendor governance, safety systems and processes, aggregate reporting operations, partner interfaces, and operational readiness while developing leaders and serving as a key advisor to cross-functional stakeholders.